Mission and Values
At tonic bioventures, we leverage early regulatory and clinical development expertise to identify, validate and advance breakthrough drugs and medical technologies through innovative companies that can transform the lives of patients, while reducing healthcare costs and time to market.
By starting with big ideas and fostering collaboration with a team of experts and advisors in science, medicine, business operations and strategy, we set out to do more than funding startups – we provide the tonic to build sustainable, innovative companies that can transform the lives of patients.
Our 5-Step Approach
We Invest in Life Sciences Assets with an Approach that Reduces the Most Common Investment Risks
We Identify true innovation from high-impact science and technology
We leverage science and experience to guide clinical translation and regulatory approval
We create the right business model, defined by and managed by an experienced Operating Partner
We efficiently mature technology utilizing on demand services
Our portfolio spans a spectrum of investment approaches from asset-centric product plays to big science product platforms.
Entrepreneurial Process is our How
We harness science to navigate transformational outcomes in healthcare that benefits the patients we serve.
We leverage CSSi LifeSciences CRO for leading scientific, regulatory and managerial talent for our portfolio companies to help them create best in class teams.
We guide our venture operators in the exploration and validation of proprietary platform opportunities across multiple therapeutic areas.
We create and provide each NewCo with an ecosystem and the resources that focuses on accelerating new product development, while mitigating risks, time and costs.
Grow each NewCo and exit to strategic partners or attract investors to grow and transform NewCo.
As primary resource providers and principal owners of NewCo’s we take full responsibility for their success.
We aim to deliver extraordinary returns by creating the world’s most innovative and valuable life sciences companies.